DHR (Danaher) Growth Rank : 8 (As of Apr. 05, 2025)

View and export this data going back to 1986. Start your Free Trial

What is Danaher Growth Rank?

Danaher has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of Danaher's Growth Rank

For the Diagnostics & Research subindustry, Danaher's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Danaher's Growth Rank Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Growth Rank distribution charts can be found below:

* The bar in red indicates where Danaher's Growth Rank falls into.

Save Embed

;

Save Embed

;

Danaher Growth Rank Related Terms

Thank you for viewing the detailed overview of Danaher's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Danaher Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

DHR:Mexico 1DHR:Italy DAPd:UK 0R2B:UK DAP:Germany DAP:Germany DAP:Germany DHER34:Brazil DHRC:Austria

Address

2200 Pennsylvania Avenue, North West, Suite 800W, Washington, DC, USA, 20037-1701

Website

https://www.danaher.com

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Executives

Alan G Spoon	director	1150 15TH ST NW, WASHINGTON DC 20071
Brian W Ellis	officer: Senior Vice President - GC	2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037
Daniel Raskas	officer: VP-Corporate Development	2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Georgeann Couchara	officer: SVP, Human Resources	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Linda Filler	director	2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew	officer: EVP & Chief Financial Officer	2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Rainer Blair	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr	director	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Teri List	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos	officer: SVP, Chief Scientific Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Raymond C Stevens	director	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt	officer: Executive Vice President	2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan	director	C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales	director, officer: Chairman of Exec. Committee	11790 GLEN ROAD, POTOMAC MD 20854